Epiduo

Epiduo is a brand name of adapalene/benzoyl peroxide topical, approved by the FDA in the following formulation(s):

EPIDUO (adapalene; benzoyl peroxide - gel; topical)

• 
  Manufacturer: GALDERMA LABS
  
  Approval date: December 8, 2008
  
  Strength(s): 0.1%;2.5% ^[RLD]

Has a generic version of Epiduo been approved?

No. There is currently no therapeutically equivalent version of Epiduo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epiduo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
  Patent 7,820,186
  Issued: October 26, 2010
  Inventor(s): Orsoni; Sandrine & Willcox; Nathalie
  Assignee(s): Galderma Research & Development
  Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.
  
  Patent expiration dates:
  
  
  • November 23, 2025
    
    ✓ 
    Drug product
  
  



• 
  Method for treatment of common acne
  Patent 7,964,202
  Issued: June 21, 2011
  Inventor(s): Orsoni; Sandrine & Willcox; Nathalie
  Assignee(s): Galderma Research & Development, S.N.C.
  Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4° C. to 40° C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress τ for a given rate gradient γ and which measure a rate gradient γ for a given shear stress τ, the yield value (τ0) being extrapolated visually or by calculation.
  
  Patent expiration dates:
  
  
  • September 1, 2024
    
    ✓ 
    Patent use: TREATMENT OF ACNE
    ✓ 
    Drug product
  
  



• 
  Combinations of adapalene and benzoyl peroxide for treating acne lesions
  Patent 8,071,644
  Issued: December 6, 2011
  Inventor(s): Abou-Chacra Vernet; Marie-line & Gross; Denis & Loesche; Christian & Poncet; Michel
  Assignee(s): Galderma Research & Development
  Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
  
  Patent expiration dates:
  
  
  • July 18, 2027
    
    ✓ 
    Patent use: TREATMENT OF ACNE
    ✓ 
    Drug product
  
  



• 
  Combinations of adapalene and benzoyl peroxide for treating acne lesions
  Patent 8,080,537
  Issued: December 20, 2011
  Inventor(s): Abou-Chacra Vernet; Marie-line & Gross; Denis & Loesche; Christian & Poncet; Michel
  Assignee(s): Galderma Research & Development
  Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
  
  Patent expiration dates:
  
  
  • July 18, 2027
    
    ✓ 
    Patent use: TREATMENT OF ACNE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 8, 2011 - NEW COMBINATION
  
  

See also...

• Epiduo Consumer Information (Drugs.com)
• Epiduo Gel Consumer Information (Wolters Kluwer)
• Epiduo topical Consumer Information (Cerner Multum)
• Epiduo Advanced Consumer Information (Micromedex)
• Adapalene and Benzoyl Peroxide Gel Consumer Information (Wolters Kluwer)
• Adapalene and benzoyl peroxide topical Consumer Information (Cerner Multum)
• Adapalene and benzoyl peroxide Topical application Advanced Consumer Information (Micromedex)